Apoha
Apoha provides a molecular-data platform that teaches AI to understand matter, enabling better design of medicines, food, and materials.
- Business Profile
- Founders & Team4 sources scanned
- Market Size7 sources scanned
- Competitor Research5 sources scanned
- Funding7 sources scanned
- Momentum4 sources scanned
- Customer Sentiment5 sources scanned
- AI Visibility
- Risks & Red Flagspublic record checked
Summary
Worth a closer lookApoha is a software-first molecular-data platform (commercial product: VIBE) that uses AI to 'understand matter' and accelerate early discovery for medicines, food and materials; it publicly reports ~40 active projects, a multi‑year partnership with Boehringer Ingelheim, and a 31-person team led by co‑founders Shamit and Anshika Srivastava. Its wedge versus incumbents like Charles River Laboratories and Malvern Panalytical is cloud-native predictive analytics and integrated molecular data for earlier go/no‑go decisions rather than selling wet‑lab services or instruments. The company’s June 2026 emergence from stealth tied to a disclosed $36M cumulative raise (Singular lead, participation from Draper Associates, Redalpine, Seedcamp, Wilbe, Nucleus, plus Innovate UK grant) signals accelerating commercialization and investor conviction. The single biggest tension is commercial depth: ACV, pilot-to‑paid conversion, and whether proprietary data/models create a sustainable moat versus better‑funded CROs/hardware vendors. For a first meeting, focus on actual revenue, customer references and the Boehringer deal economics.
Bull case
- Disclosed $36M cumulative funding (spring 2026 raise led by Singular with participation from Draper Associates, Redalpine, Seedcamp, Wilbe and Nucleus, plus Innovate UK grant) — recent capital and grant support to scale commercialization.
- Commercial product VIBE with ~40 active projects and an announced multi‑year partnership with Boehringer Ingelheim — evidence of early enterprise traction and pharma validation.
- Software-first positioning that complements (rather than replaces) CROs/instrument vendors, targeting earlier discovery where predictive models can materially speed go/no‑go decisions.
- Founding team continuity (Shamit Shrivastava, CEO; Anshika Srivastava, COO) and a 31-person headcount as of Apr 30, 2026 — practical operating scale for an early-stage commercial push.
Watch-outs
- Customer evidence is thin and largely company-sourced: only a single named scientist testimonial and no independent aggregate customer ratings or multiple third‑party references.
- Competitive pressure from entrenched, better‑capitalized players (Charles River, Malvern) with existing customer relationships and complementary offerings could blunt enterprise adoption.
- Key commercial metrics are undisclosed (ACV/pricing, ARR, pilot-to‑paid conversion, churn), leaving unit economics and runway ambiguous despite the $36M disclosed funding.
- Low unprompted visibility in category-level AI outputs suggests limited market awareness or share relative to peers, raising go‑to‑market and demand‑generation questions.
Questions for the founder
- 1What is current ARR, ACV range, and gross margin by customer segment?
- 2What percentage of pilots convert to paid engagements and typical sales cycle length?
- 3What are the commercial and revenue terms of the Boehringer Ingelheim partnership (revenue, milestones, exclusivity)?
- 4What proprietary data, models, or IP form a defensible moat versus CROs/instrument vendors, and how is it licensed/protected?
- 5How is the 31-person team allocated across R&D, data ops, and commercial functions (heads in sales/CS vs engineering)?
Company profile
Customers on site
Pricing
Not publicly disclosed. The company website does not list its pricing on any of the 6 pages we read.
Press
Target segments
Key features
- VIBE® (Variations in Inter-facial Behaviour Under Excitation)
Measures molecular behaviour in liquid under controlled stresses; generates over 1,000 numerical descriptors to predict stability, texture and performance
- Liquid Brain®
Liquid-state device that captures sensory 'fingerprints' of complex molecules using nonlinear Lucassen waves for rapid property classification
- Insights Platform
Workspace for scientists integrating sequences, assays, predictive models, analytics and instant reporting for hit-to-lead triage
Stats they publish
Testimonials
“"Apoha unlocked a characterization space for clinically relevant serum samples. We saw clear signals that can boost the predictive power of our models and contribute to disease diagnosis - signals we cannot feasibly capture otherwise." Tristan Deli, PhD Co-founder, CTO”
Tristan Deli · PhD Co-founder, CTO“"We chose Apoha because conventional assays just down show this data. We’re now integrating Apoha’s platform at the very start of our next program." Estelle Beguin, PhD Director Technology Research”
Estelle Beguin · PhD Director Technology Research“"... Apoha’s Liquid Brain can distinguish between different classes of oils, including those that are chemically similar in composition …Further, the readings from Apoha’s signatures correlated with the independent biophysical property measurements. … This technology can therefore help design sensorially similar or superior formulations and reduce / remove dependence on customer testing to validate the degree of similarity. This could be commercially significant, potentially reducing product failure rates, and the product testing cycle from several months to days."”
Nimish Gera · PhD Scientific Co-Founder, VP“"We gave >20 proteins for Apoha to characterise, which would have taken months through the traditional methods, and would have come at a high cost for renting specific equipment. Apoha did it in a couple of days! Apoha’s insights enabled us to formulate a new product in record time – their proprietary feature vectors provided direct comparison of proteins and their interchangeability. We achieved in days what usually takes months..."”
Nimish Gera · PhD Scientific Co-Founder, VP“"We’ve now worked with Apoha across multiple pilot programs, including a recent 70-antibody case study on a novel modality. In one early study, Liquid Brain correctly flagged liabilities between antibodies that differed by just 1–2 amino acids! Based on these results, we’re now integrating Liquid Brain at the very start of our next program to get developability insights right at hit identification."”
Michael Marlow · PhD Director, Biologics“"Apoha’s platform is exactly the type of technology that regulators are pushing for and the industry is looking for… fingerprint-like analytical data, multidimensional, relating structure to function."”
Rafiq Islam · President
Founders & Team
2- Anshika SrivastavaFounderCo-Founder & Chief Operating OfficerDartmouth-trained engineer and former Goldman Sachs Executive Director who led engineering teams.
- Shamit ShrivastavaFounderCo-Founder & CEOPreviously held roles at University of Oxford and Boston University; noted to hold a Ph.D. from Boston University.
Publicly named leadership consists of two co-founders: Shamit Shrivastava (Co-founder & CEO) and Anshika Srivastava (Co-founder & COO), cited by Tracxn and press. No additional company-owned team roster with named executives was found in the provided company site snippets.
- Founders and roles are drawn from Tracxn and corroborating press; Apoha's public site snippets provided did not show a detailed team page with named leadership.
- Some aggregators list other team members (e.g., Pratik Kotkar as VP Engineering) and slightly different headcounts (29 vs 31); those individuals were not verifiable on the company site in the provided sources and therefore were omitted.
- Team size is taken from Tracxn's stated employee count (31 as of Apr 30, 2026) and may differ across data providers.
Market Size
No published top-down market size was located specifically for 'molecular-data-platform' B2B SaaS. As an evidence-backed, conservative proxy for a life-sciences software-adjacent market, published global molecular-diagnostics market estimates range from USD 14B (2024) to USD 20.41B (2026); however this category is materially different from Apoha's molecular-design software addressable market. A bottom-up SAM and a SOM cannot be computed because Apoha's ACV/pricing is not publicly available.
- Mordor Intelligence ↗Market Size (2026) USD 20.41 Billion; Market Size (2031) USD 33.51 Billion; Growth Rate (2026 - 2031) 10.43% CAGR · Global · 10.43% CAGR
- Future Market Insights ↗USD 17.1 billion (2025); projected to USD 41.5 billion by 2036 at a CAGR of 8.4% · Global · 8.4% CAGR
- MarketDataForecast ↗The global molecular diagnostics market size was worth USD 14 billion in 2024. · Global
- Number of pharmaceutical companies with active R&D pipelines (global, 2026)7,057 companieshttps://www.statista.com/statistics/791340/pharmaceutical-companies-number-with-active-pipeline/
- Number of biotech companies (global, database listing)722,852 companies (company-data listing)https://companydata.com/companies/world/biotech-companies/
- Apoha ACV / pricingNo public ACV/pricing found — cannot compute bottom-up SAMApoha public information (no pricing captured)
- TAM is an adjacent-market proxy (molecular diagnostics) because no published figure was found for 'molecular-data-platform' or computational molecular-design B2B SaaS specifically; molecular diagnostics focuses on clinical testing (instruments, reagents, software) and is therefore a broader/different revenue base than Apoha's R&D/design software.
- SAM not computed (set to null) because Apoha's ACV/pricing was not found; bottom-up SAM requires customer count × ACV and ACV would be speculative.
- SOM not computed (set to null) because there is no grounded SAM to apply an obtainable-share to.
- Customer counts used as contextual inputs (pharma = 7,057; biotech = 722,852) come from public databases and may include very small companies, subsidiaries, and inactive entities — they are indicative, not a validated addressable-customer list.
Competitors
Top 2Competitive set spans instrument manufacturers and CROs with cloud platforms; Apoha occupies the software-first niche — integrated molecular-data and predictive analytics for early-stage discovery, complementing but not replacing wet‑lab providers.
- Charles River Laboratoriescharlesrivercampus.com ↗Global CRO offering preclinical/clinical lab services and Apollo cloud for toxicology; Apoha targets earlier discovery with molecular-data integration and predictive models, not CRO wet-lab services.
- Malvern Panalyticalmalvernpanalytical.com ↗Provides laboratory analytical instruments for particle/biomolecular characterization; Apoha differentiates by offering cloud-based molecular-data integration and predictive analytics for early discovery, not hardware-based measurements.
Funding
- Seed2024RedalpineSeedcampWilbeNucleusFortune ↗
- Unlettered roundSpring 2026Singular leadDraper AssociatesRedalpineSeedcampWilbeNucleusTech Funding News ↗
- Grant2026Innovate UKTech Funding News ↗
Press coverage in June 2026 reports a $36M cumulative raise for Apoha; outlets name a 2024 seed and a recent (spring 2026) unlettered financing led by Singular with participation from Draper Associates and continued backing from Redalpine, Seedcamp, Wilbe and Nucleus, plus grant support from Innovate UK. Individual round amounts were not broken out publicly.
- Multiple reputable outlets report a $36M total (June 2026), but reporting differs on how that figure is structured: several outlets labeled the announcement a 'Series A', while Fortune issued a correction saying the $36M is the cumulative amount from a 2024 seed and a recent unlettered round. The public record here does not break out amounts by round.
- Tracker/database summaries conflict with the $36M figure: PitchBook and some company-tracking pages list lower lifetime totals (examples in the provided material: PitchBook cited ~$10.3M; other aggregator lines cited ~$16.13M). Those lower totals are inconsistent with the press coverage of a $36M cumulative amount.
- Round-level investor participation is reported in press copy (Singular lead; Draper Associates and 'continued backing' from Redalpine, Seedcamp, Wilbe, Nucleus). Investors were assigned to specific rounds here only when the text explicitly tied them to that round (seed investors named as such in 2024; Singular and Draper named as participating in the latest raise).
- No reliable structured Crunchbase/PitchBook round entries were provided to reconcile discrepancies; itemised (per-round) amounts other than the $36M cumulative figure were not disclosed in the cited coverage.
- The $36M figure is treated here as the disclosed company-level total; the itemised rounds in this extract are those explicitly mentioned in coverage (2024 seed; spring 2026 unlettered; an Innovate UK grant).
Momentum
- FundingJune 3, 2026Emerges from stealth and announces $36M in funding (announced at SXSW London)TNW ↗
- FundingJune 3, 2026Latest funding led by Singular with participation from Draper Associates and continued seed backers; grant funding from Innovate UK reportedTNW ↗
- PartnershipJune 3, 2026Reports multi-year research partnership with Boehringer Ingelheim that identified high‑risk antibody candidates with >90% precisionFortune ↗
- LaunchJune 3, 2026Says first commercial product is VIBE, an empirical readout of molecular behaviourTNW ↗
- MilestoneJune 3, 2026Platform reported to be already in commercial useTNW ↗
- MilestoneJune 3, 2026Says it has completed about 40 customer projects to dateFortune ↗
- MilestoneJune 3, 2026Company headcount reported at about 25 employeesFortune ↗
- Funding2024Seed round completed in 2024 (part of cumulative $36M disclosed)Fortune ↗
- FundingSpring 2026Unlettered funding round completed in Spring 2026 (part of the $36M total)Fortune ↗
Public signals concentrate in early June 2026: the company publicly emerged from stealth tied to a $36M funding disclosure (led by Singular with grant support from Innovate UK), while reporting a commercial product (VIBE), active customers (~40 projects) and a multi‑year pharma partnership with Boehringer Ingelheim. These date-stamped items point to accelerating commercialization and fundraising momentum.
- Most dated signals come from June 3, 2026 press coverage and largely reflect company announcements and reported benchmarks; independent third‑party validation of those benchmarks is limited in the reporting.
- Fortune issued a correction clarifying the $36M figure is cumulative (2024 seed + an unlettered spring 2026 round) rather than a single labelled Series A; funding descriptions therefore mix rounds.
- Several claims (Boehringer results, commercial use, customer counts) are reported in the same set of articles and may originate from company disclosures or preprints rather than peer‑reviewed publications.
Customer Sentiment
Public customer feedback for the Apoha molecular-data platform is minimal and limited to company marketing plus a single named scientist testimonial praising the Insights Platform for putting state-of-the-art models into experimentalists' hands, enabling larger-volume assay analysis, reproducibility, and earlier go/no-go decisions. There are no independent third-party aggregate ratings or multiple customer reviews available to assess broader customer sentiment.
Most accessible documents reference the philosophical concept or books titled “Apoha,” not the molecular-data company; those academic reviews are unrelated to the company’s product.
Only on-site marketing copy and a single testimonial from Dr Nimish Gera explicitly comment on the company’s Insights Platform.
No numeric aggregate ratings or reviews from independent platforms (e.g., Trustpilot, G2, Capterra, App Store) are present for the company in the available material.
A Glassdoor listing is mentioned but no employee reviews or ratings are quoted here.
Possible name collision between academic/philosophical sources and the company prevents attributing many retrieved items to the business.
AI Visibility
We ask ChatGPT WITH web search about the company and show its answers plus the sources it cited — the real AI-search experience. The key signal is share of voice: does the company come up when AI is asked about its space, not just when asked by name.
Models asked ChatGPT · web search
Accuracy of what AI said: Accurate — Direct reply correctly identifies Apoha’s Liquid State Intelligence / VIBE technology, founders, recent $36M round, employee count and patent assertions as reported in the cited coverage.
Apoha is a London-based deep tech company specializing in "Liquid State Intelligence," a novel data layer that empirically measures molecular behavior under real-world conditions. This technology aims to enhance the design and development processes in pharmaceuticals, food, and materials by providing insights into how molecules and materials behave. (tech.eu)
Founders and Leadership: Apoha was co-founded in 2021 by Dr. Shamit Shrivastava, who serves as the CEO, and Anshika Srivastava, the COO. Dr. Shrivastava's research on molecular behavior has been widely recognized, including being named one of Scientific American’s "13 Discoveries That Could Change Everything" in 2018. (tech.eu)
Company Size and Stage: As of 2026, Apoha has approximately 28 employees and is in the seed funding stage. The company recently emerged from stealth mode, announcing a $36 million funding round led by Singular, with participation from Draper Associates and continued support from seed investors such as Redalpine, Seedcamp, Wilbe, and Nucleus. Additionally, Apoha has received grant funding from Innovate UK. (tech.eu)
Notable Facts:
- VIBE® Technology: Apoha's flagship product, VIBE® (Variations in Inter-facial Behaviour Under Excitation), provides empirical data on how molecules and materials behave under real-world conditions. This technology involves analyzing minute samples suspended in liquid, applying controlled stresses, and capturing the resulting wave patterns to understand molecular behavior. (tech.eu)
- Intellectual Property: The company holds over 60 patents covering hardware, software, data, and AI models related to their Liquid State Intelligence platform. (tech.eu)
- Industry Partnerships: Apoha collaborates with organizations like Somru BioSciences and multiple Fortune 500 companies across the pharmaceutical, food and beverage, and materials sectors to apply their technology in various applications. (tech.eu)
Apoha's innovative approach to understanding molecular behavior positions it as a significant player in advancing AI applications in the physical sciences.
Here is a concise list of notable companies and products in the molecular data platform space:
- DNAnexus: Provides a cloud-based data analysis and management platform for DNA sequence data. (en.wikipedia.org)
- Bioz: Offers an AI-powered search engine for life science experimentation, assisting researchers in selecting lab tools and reagents. (en.wikipedia.org)
- BIOBASE: Specializes in bioinformatics databases and software platforms for molecular biology research. (en.wikipedia.org)
- OpenEye Scientific Software: Develops molecular modeling applications and toolkits for drug discovery and materials science. (en.wikipedia.org)
- GeneDx: Focuses on genomic diagnostics, particularly whole genome and exome sequencing for rare and inherited disorders. (en.wikipedia.org)
- Schrödinger, Inc.: Provides computational tools and software for drug discovery and materials science, including molecular modeling programs. (en.wikipedia.org)
- Illumina, Inc.: A pioneer in integrated systems for analyzing genetic variation and biological function. (marketsandmarkets.com)
- Thermo Fisher Scientific, Inc.: Offers a diverse portfolio of genomic analysis solutions and advanced bioinformatics platforms. (marketsandmarkets.com)
- Eurofins Scientific: Provides a vast international network of laboratory services, including next-generation and custom DNA sequencing. (marketsandmarkets.com)
- Seven Bridges Genomics: Recognized as a leading vendor in the genomic data federation platforms market, with deep partnerships in research consortia. (dataintelo.com)
- SOPHiA GENETICS: Operates the SOPHiA DDM platform, connecting over 780 hospital customers across 70 countries through a cloud-native federation architecture. (dataintelo.com)
These companies are at the forefront of molecular data platforms, offering a range of solutions from genomic sequencing to bioinformatics and computational tools.
In the molecular data platform space, several companies offer innovative solutions for integrating, analyzing, and managing complex biological data. Here are some notable examples:
Genedata Genedata provides enterprise software solutions to accelerate biopharmaceutical research and development. Their platform supports the discovery, development, and translational research of biotherapeutics, including antibodies, cell and gene therapies, RNA, and vaccines. In July 2024, Genedata joined the Danaher Group. (en.wikipedia.org)
Precision Health Data Cloud for Academic Medical Centers | DNAnexus® DNAnexus DNAnexus offers a cloud-based data analysis and management platform for DNA sequence data. Founded in 2009, the company provides infrastructure to handle large-scale genomic data, facilitating collaboration and analysis in the field of genomics. (en.wikipedia.org)
Molecular Modeling Toolkits | OpenEye Scientific OpenEye Scientific Software OpenEye Scientific Software develops large-scale molecular modeling applications and toolkits. Founded in 1997, the company focuses on providing computational solutions for molecular design and analysis. In September 2022, OpenEye was acquired by Cadence Design Systems and rebranded as OpenEye Cadence Molecular Sciences. (en.wikipedia.org)
Introduction to LabKey Server: /Documentation LabKey LabKey Server is a software suite designed for scientists to integrate, analyze, and share biomedical research data. The platform offers a secure data repository with web-based querying, reporting, and collaboration capabilities across various data sources. (en.wikipedia.org)
Pluto Bio • Pluto Bio • Multi-omics platform for translational discovery Pluto Bio Pluto Bio provides a multi-omics platform for translational discovery, enabling researchers to analyze and visualize complex biological data. The platform supports various applications, including target discovery and biomarker identification. (pluto.bio)
These companies offer diverse platforms tailored to the needs of researchers and organizations working with molecular data, facilitating advancements in fields such as genomics, proteomics, and drug discovery.
The assistant did not surface Apoha unprompted among notable molecular-data-platform vendors, but when asked by name it returned a timely and accurate profile. For a VC, this indicates Apoha has low unprompted visibility in category-level outputs even though its direct description appears reliable.
- AI answers and web-citation availability can vary between runs and over time; this assessment is based on the provided outputs.
- Category/recommendation lists shown here skew toward established genomics/bioinformatics vendors and may miss recent deep‑tech entrants that only appear in recent press (e.g., 2026 coverage).
- If new funding or hires have occurred since the cited article, those would not be reflected here.
Risks & Red Flags
No material public risk signals found. An absence of public concerns isn’t a clean bill of health — early or private companies may simply not generate coverage.
No publicly reported concerns were located in the reviewed sources. That absence does not rule out undisclosed or private disputes, regulatory enquiries, security incidents, or customer issues.
Early-stage and privately held companies often generate limited public records; direct diligence (reference checks, counsel review of contracts/ IP, and a cybersecurity assessment) is recommended before investment.
Frequently asked questions
What does Apoha do?
Apoha provides a molecular-data platform that teaches AI to understand matter, enabling better design of medicines, food, and materials.
How much funding has Apoha raised?
Apoha has raised $36M in disclosed funding. Its most recent disclosed round was a Unlettered round in 2026, led by Singular.
Who are Apoha's main competitors?
Apoha's named competitors include Charles River Laboratories and Malvern Panalytical.
Who founded Apoha?
Apoha was founded by Anshika Srivastava and Shamit Shrivastava.
Where is Apoha headquartered?
Apoha is headquartered in London, United Kingdom.
What market does Apoha operate in?
Apoha operates in the Molecular data platform market (B2B). Its total addressable market is estimated at USD 20.41 billion (2026) — global molecular diagnostics market (published proxy; adjacent to molecular-data-platform software).
How does Apoha's pricing work?
Apoha uses a enterprise custom pricing model.
Compiled by AlgoTurk from public web sources · . Not investment advice.